Log in

Relevant bibliographies by topics / BCVA-Best Corrected Visual Acuity CSME-Clinically Significant Macular Edema VEGF-Vascular Endothelial Growth Factor V.A.-Visual Acuity OCT=Optical Coherence Tomography

Contents

Journal articles

Academic literature on the topic 'BCVA-Best Corrected Visual Acuity CSME-Clinically Significant Macular Edema VEGF-Vascular Endothelial Growth Factor V.A.-Visual Acuity OCT=Optical Coherence Tomography'

Author: Grafiati

Published: 5 June 2025

Last updated: 1 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'BCVA-Best Corrected Visual Acuity CSME-Clinically Significant Macular Edema VEGF-Vascular Endothelial Growth Factor V.A.-Visual Acuity OCT=Optical Coherence Tomography.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "BCVA-Best Corrected Visual Acuity CSME-Clinically Significant Macular Edema VEGF-Vascular Endothelial Growth Factor V.A.-Visual Acuity OCT=Optical Coherence Tomography"

1

Yozgat, Zübeyir. "Optical Coherence Tomography-Guided Early Versus Late Switching to Dexamethasone Implants in Macular Edema Related to Central Retinal Vein Occlusion: Real-World Evidence." Diagnostics 15, no. 4 (2025): 439. https://doi.org/10.3390/diagnostics15040439.

Full text

Abstract:

Background/Objectives: This study evaluated the outcomes of early versus late switching from intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy to dexamethasone (DEX) implants in patients with macular edema secondary to central retinal vein occlusion (CRVO). The critical role of optical coherence tomography (OCT) in guiding therapeutic decisions and monitoring treatment responses is emphasized. Methods: In this real-world, retrospective study, 61 treatment-naïve CRVO patients were divided into two groups: Group 1 (early switch after three anti-VEGF injections) and Group 2

APA, Harvard, Vancouver, ISO, and other styles

2

Liang, I.-Chia, Hsin-Ching Shen, Yun-Hsiang Chang, and Shu-I. Pao. "The Responses of Different Types of Diabetic Macular Edema after Three Loading Doses of Anti-vascular Growth Factor: Outcomes in Two Medical Centers." Journal of Medical Sciences 44, no. 3 (2024): 119–24. http://dx.doi.org/10.4103/jmedsci.jmedsci_187_23.

Full text

Abstract:

Background: Diabetic macular edema (DME) is currently treated by anti-vascular endothelial growth factor (anti-VEGF). Aim: The aim of this study was to evaluate the effect of intravitreal anti-VEGF in different types of DME classified by optical coherence tomography (OCT). Methods: This retrospective study included 161 treatment-naive eyes (116 patients) diagnosed with DME in two tertiary medical centers, which were classified into three groups according to initial OCT finding: diffuse retinal thickening (DRT), cystoid macular edema (CME), and serous retinal detachment (SRD). All eyes received

APA, Harvard, Vancouver, ISO, and other styles

3

Okudan, Süleyman, Sule Acar Duyan, Abdullah Erdem, Ayse Bozkurt Oflaz, and Banu Turgut Ozturk. "Optical Coherence Tomography Biomarkers Predict the Long-Term Restorative Effect of Early Anti-VEGF Treatment on Diabetic Macular Edema." Life 15, no. 2 (2025): 269. https://doi.org/10.3390/life15020269.

Full text

Abstract:

Background/Purpose: This study compared the effects of three induction doses of anti-vascular endothelial growth factor (anti-VEGF) on diabetic macular edema (DME) with that of long-term treatment using biomarkers to find out the predictability potential of early response to anti-VEGF treatment for the long-term restorative effect. Methods: We retrospectively reviewed the clinical and optical coherence tomography (OCT) data of 71 DME eyes treated with three monthly anti-VEGF doses and followed for 1 year. BCVA, central subfield thickness (CST), subretinal fluid (SRF), intraretinal cysts, hyper

APA, Harvard, Vancouver, ISO, and other styles

4

Gu, Zheyao, Xiangying Luo, Ruizhu Sun, Ting Xi, and Chunyuan Zhang. "Long-term effects of the COVID-19 lockdown on the structural and functional outcomes of neovascular AMD patients in Suzhou, China." PLOS ONE 20, no. 3 (2025): e0319677. https://doi.org/10.1371/journal.pone.0319677.

Full text

Abstract:

Background Timely anti-vascular endothelial growth factor (VEGF) therapy is essential for visual function in neovascular age-related macular degeneration (nAMD). The coronavirus pandemic has led to unprecedented delays in anti-VEGF intravitreal therapy because of the need to reduce hospital attendance. Objectives To assess the long-term impact of COVID-19 pandemic-related delays in intravitreal anti-VEGF therapy on nAMD patients. Methods This was a retrospective study of 98 patients (102 eyes) with nAMD whose anti-VEGF treatments were interrupted for > 8 weeks due to the COVID-19 pandemic.

APA, Harvard, Vancouver, ISO, and other styles

5

Tang, Li, Yue Zhao, Ting-Ting Yang, and Jin Yao. "Optical coherence tomography angiography for macular microvessels in ischemic branch retinal vein occlusion treated with conbercept: predictive factors for the prognosis." International Journal of Ophthalmology 16, no. 12 (2023): 2049–55. http://dx.doi.org/10.18240/ijo.2023.12.18.

Full text

Abstract:

AIM: To evaluate the predicative factors of visual prognosis using optical coherence tomography angiography (OCTA) in ischemic branch retinal vein occlusion (BRVO) patients with macular edema (ME) after anti-vascular endothelial growth factor (VEGF) treatment. METHODS: In this retrospective analysis, data from 60 patients (60 eyes) with a definite diagnosis of ischemic BRVO with ME by fundus fluorescein angiography (FFA) were studied. The eyes with ME according to spectral domain optical coherence tomography (SD-OCT) underwent intravitreal conbercept (IVC) and 3+pro re nata (PRN) regimen. The

APA, Harvard, Vancouver, ISO, and other styles

6

Hafner, Michael, Tina R. Herold, Alexander Kufner, et al. "Switching to Faricimab in Therapy-Resistant Macular Edema Due to Retinal Vein Occlusion: Initial Real-World Efficacy Outcomes." Journal of Clinical Medicine 14, no. 7 (2025): 2454. https://doi.org/10.3390/jcm14072454.

Full text

Abstract:

Background/Objectives: Macular edema (ME), due to retinal vein occlusion (RVO), is a major cause of vision impairment. Many patients experience suboptimal responses to anti-vascular endothelial growth factor (anti-VEGF) monotherapy, necessitating alternative treatment approaches. Faricimab, a bispecific antibody targeting VEGF-A and angiopoietin-2 (Ang-2), introduces a novel dual-mechanism therapy. This study evaluates the short-term real-world efficacy of switching to Faricimab in patients with treatment-resistant ME secondary to RVO. Methods: This retrospective study included patients from L

APA, Harvard, Vancouver, ISO, and other styles

7

Ramzi Amin and Oliffa Salma Atthahiroh. "Successful Management of Central-Involving Diabetic Macular Edema with Sequential Anti-VEGF Injections in Moderate NPDR: A Case Study." Archives of The Medicine and Case Reports 5, no. 2 (2024): 691–704. https://doi.org/10.37275/amcr.v5i2.741.

Full text

Abstract:

Diabetic macular edema (DME), particularly central-involving DME (CI-DME), represents a primary cause of significant vision impairment among individuals afflicted with diabetic retinopathy (DR). The progression from non-proliferative diabetic retinopathy (NPDR) stages can be complicated by the development of CI-DME, which mandates prompt and effective intervention to preserve visual function. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents have emerged as the definitive first-line therapeutic strategy for CI-DME, demonstrating considerable efficacy in reducing macular t

APA, Harvard, Vancouver, ISO, and other styles

8

Dr. Ahmad Hassan, Dr. Aleem Hamza Bajwa, and Dr. Muhammad Kashif Bilal. "<b>EVALUATION OF VISUAL AND ANATOMICAL OUTCOMES AFTER INTRA-VITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTION IN PATIENTS WITH DIABETIC DIFFUSE MACULAR EDEMA</b>." Journal of Medical & Health Sciences Review 2, no. 3 (2025). https://doi.org/10.62019/p8r0dq65.

Full text

Abstract:

Aim: This study aimed to evaluate the visual and anatomical outcomes following intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections in patients with diffuse diabetic macular edema (DME). The primary objective was to assess improvement in best-corrected visual acuity (BCVA) and reduction in central retinal thickness (CRT) as measured by spectral domain optical coherence tomography (OCT). Methods: A descriptive cross-sectional study was conducted at the Ophthalmology Department of Bahawal Victoria Hospital, Bahawalpur, over a six-month period. A total of 147 treatment-naïv

APA, Harvard, Vancouver, ISO, and other styles

9

Dr. Ahmad Hassan, Dr. Aleem Hamza Bajwa, and Dr. Muhammad Kashif Bilal. "<b>EVALUATION OF VISUAL AND ANATOMICAL OUTCOMES AFTER INTRA-VITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTION IN PATIENTS WITH DIABETIC DIFFUSE MACULAR EDEMA</b><sup></sup>." Journal of Medical & Health Sciences Review 2, no. 3 (2025). https://doi.org/10.62019/x5z56a52.

Full text

Abstract:

Aim: This study aimed to evaluate the visual and anatomical outcomes following intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections in patients with diffuse diabetic macular edema (DME). The primary objective was to assess improvement in best-corrected visual acuity (BCVA) and reduction in central retinal thickness (CRT) as measured by spectral domain optical coherence tomography (OCT). Methods: A descriptive cross-sectional study was conducted at the Ophthalmology Department of Bahawal Victoria Hospital, Bahawalpur, over a six-month period. A total of 147 treatment-naïv

APA, Harvard, Vancouver, ISO, and other styles

10

Veiga Reis, Francyne, Pedro Dalgalarrondo, José Edisio da Silva Tavares Neto, Murilo Wendeborn Rodrigues, Ingrid U. Scott, and Rodrigo Jorge. "Combined intravitreal dexamethasone and bevacizumab injection for the treatment of persistent diabetic macular edema (DexaBe study): a phase I clinical study." International Journal of Retina and Vitreous 9, no. 1 (2023). http://dx.doi.org/10.1186/s40942-023-00449-w.

Full text

Abstract:

Abstract Purpose The aim of this study is to investigate the safety of combined intravitreal injection of dexamethasone aqueous-solution (IVD) and bevacizumab (IVB) in patients with refractory diabetic macular edema (DME) and its effect on intraocular pressure (IOP), best-corrected visual acuity (BCVA) and central subfield thickness (CSFT). Methods This prospective study included 10 patients (10 eyes) with DME refractory to laser photocoagulation and/or anti-vascular endothelial growth factor (anti-VEGF) therapy. A complete ophthalmological examination was performed at baseline, during the fir

APA, Harvard, Vancouver, ISO, and other styles

More sources

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!